212 related articles for article (PubMed ID: 9710622)
1. Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor.
Castaño E; Kleyner Y; Dynlacht BD
Mol Cell Biol; 1998 Sep; 18(9):5380-91. PubMed ID: 9710622
[TBL] [Abstract][Full Text] [Related]
2. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity.
Woo MS; Sánchez I; Dynlacht BD
Mol Cell Biol; 1997 Jul; 17(7):3566-79. PubMed ID: 9199292
[TBL] [Abstract][Full Text] [Related]
3. The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain.
Joaquin M; Watson RJ
J Biol Chem; 2003 Nov; 278(45):44255-64. PubMed ID: 12947099
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
5. Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p16INK4A(+) tumor cells.
Cheng L; Rossi F; Fang W; Mori T; Cobrinik D
J Biol Chem; 2000 Sep; 275(39):30317-25. PubMed ID: 10906146
[TBL] [Abstract][Full Text] [Related]
6. Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression.
Hashimoto Y; Kohri K; Kaneko Y; Morisaki H; Kato T; Ikeda K; Nakanishi M
J Biol Chem; 1998 Jun; 273(26):16544-50. PubMed ID: 9632724
[TBL] [Abstract][Full Text] [Related]
7. E1A modulates phosphorylation of p130 and p107 by differentially regulating the activity of G1/S cyclin/CDK complexes.
Parreño M; Garriga J; Limón A; Albrecht JH; Graña X
Oncogene; 2001 Aug; 20(35):4793-806. PubMed ID: 11521191
[TBL] [Abstract][Full Text] [Related]
8. Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes.
Lacy S; Whyte P
Oncogene; 1997 May; 14(20):2395-406. PubMed ID: 9188854
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the actin cytoskeleton leads to inhibition of mitogen-induced cyclin E expression, Cdk2 phosphorylation, and nuclear accumulation of the retinoblastoma protein-related p107 protein.
Reshetnikova G; Barkan R; Popov B; Nikolsky N; Chang LS
Exp Cell Res; 2000 Aug; 259(1):35-53. PubMed ID: 10942577
[TBL] [Abstract][Full Text] [Related]
10. E2F/p107 and E2F/p130 complexes are regulated by C/EBPalpha in 3T3-L1 adipocytes.
Timchenko NA; Wilde M; Iakova P; Albrecht JH; Darlington GJ
Nucleic Acids Res; 1999 Sep; 27(17):3621-30. PubMed ID: 10446255
[TBL] [Abstract][Full Text] [Related]
11. Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation.
Kiess M; Gill RM; Hamel PA
Cell Growth Differ; 1995 Oct; 6(10):1287-98. PubMed ID: 8845306
[TBL] [Abstract][Full Text] [Related]
12. Site-directed mutant p21 proteins defective in both inhibition of E2F-regulated transcription and disruption of E2F-p130-cyclin-cdk2 complexes.
Robles SJ; Shiyanov P; Aristodemo GT; Raychaudhuri P; Adami GR
DNA Cell Biol; 1998 Jan; 17(1):9-18. PubMed ID: 9468218
[TBL] [Abstract][Full Text] [Related]
13. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
[TBL] [Abstract][Full Text] [Related]
14. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence.
Carroll JS; Prall OW; Musgrove EA; Sutherland RL
J Biol Chem; 2000 Dec; 275(49):38221-9. PubMed ID: 10991938
[TBL] [Abstract][Full Text] [Related]
15. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors.
Adams PD; Sellers WR; Sharma SK; Wu AD; Nalin CM; Kaelin WG
Mol Cell Biol; 1996 Dec; 16(12):6623-33. PubMed ID: 8943316
[TBL] [Abstract][Full Text] [Related]
16. CCAAT/enhancer-binding protein-alpha cooperates with p21 to inhibit cyclin-dependent kinase-2 activity and induces growth arrest independent of DNA binding.
Harris TE; Albrecht JH; Nakanishi M; Darlington GJ
J Biol Chem; 2001 Aug; 276(31):29200-9. PubMed ID: 11369759
[TBL] [Abstract][Full Text] [Related]
17. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes.
Nahum A; Hirsch K; Danilenko M; Watts CK; Prall OW; Levy J; Sharoni Y
Oncogene; 2001 Jun; 20(26):3428-36. PubMed ID: 11423993
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of cyclin-dependent kinase inactivation by progestins.
Musgrove EA; Swarbrick A; Lee CS; Cornish AL; Sutherland RL
Mol Cell Biol; 1998 Apr; 18(4):1812-25. PubMed ID: 9528753
[TBL] [Abstract][Full Text] [Related]
19. HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose expression blocks S-phase progression.
Hall C; Nelson DM; Ye X; Baker K; DeCaprio JA; Seeholzer S; Lipinski M; Adams PD
Mol Cell Biol; 2001 Mar; 21(5):1854-65. PubMed ID: 11238922
[TBL] [Abstract][Full Text] [Related]
20. Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4.
Leng X; Noble M; Adams PD; Qin J; Harper JW
Mol Cell Biol; 2002 Apr; 22(7):2242-54. PubMed ID: 11884610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
